Dr. Khemaies Slimane

Diplômes

• Autorisation d’exercice de Médecine en France, Oncologie Option Radiothérapie (2025)
• Diplôme Radiothérapie et curiethérapie des cancers Gynécologiques – Paris VI (2025)
• Diplôme de Radiothérapie stéréotaxique crânienne et extra-crânienne – Paris VI (2024)
• Diplôme de Radiothérapie des Cancers ORL – Université Paris XI (2023)
• Réussite aux Epreuves Classantes Nationales PAE (2022)
• Diplôme de Cancérologie Génito-Urinaire – Université Paris XI (2022)
• Cours avancés de Cancérologie et de Chimiothérapie – Gustave Roussy (2021)
• Diplôme Universitaire de Carcinologie Clinique (DUCC) – Université Paris XI (2021)
• Mastère d’excellence en médecine option Oncologie – Maison de Cancérologie Paris (2005)
• Diplôme de sénologie – Université Paris VII (2004)
• Diplôme des Cancers ORL – Université Paris XI (2003)
• Diplôme d’AFS en Oncologie Médicale – Université Paris XI (2003)
• Diplôme universitaire de formation des investigateurs aux essais cliniques – Université Paris VII (2002)
• Diplôme Universitaire de Carcinologie Clinique (DUCC) – Université Paris XI (2001)
• Cours avancés de Cancérologie et de Chimiothérapie – Gustave Roussy (2001)
• Diplôme d’Oncologie Radiothérapie – Faculté de Sousse Tunisie (2000)
• Diplôme d’AFS en Oncologie Radiothérapie – Université Paris XI (2000)
• Diplôme National de Médecine – Faculté de Sousse Tunisie (1990)

Cursus hospitalo-universitaire

• Faisant-fonction de Praticien Spécialiste des CLCC en Radiothérapie à l’Institut Godinot (depuis 2025)
• Praticien Associé en Radiothérapie et Oncologie Médicale à l’Hôpital Haut Lévêque du CHU de Bordeaux (2023-2025)
• Médecin Résident dans le Département d’Oncologie Médicale à Gustave Roussy à Villejuif (2001-2003)
• Interne dans le Service d’Oncologie Médicale de l’Hôpital Paul Brousse à Villejuif (2000-2001)
• Médecin Résident dans le Département de Radiothérapie de Gustave Roussy à Villejuif (1999-2000)
• Médecin Résident dans le Service de Radiothérapie de l’Hôpital Universitaire de Sousse et de l’Institut Saleh Azaiz en Tunisie (1996-1999)
• Interne dans les Hôpitaux de Sousse en Tunisie (1994-1996)

Sociétés savantes et groupes coopérateurs

• Membre de la Société Française de Radiothérapie Oncologique (SFRO)

Principales publications

Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced breast cancer. Lu YS, Bin Mohd Mahidin EI, Azim H, Eralp Y, Yap YS, Im SA, Rihani J, Gokmen E, El Bastawisy A, Karadurmus N, Lim YN, Lim CS, Duc LT, Chung WP, Babu KG, Penkov K, Bowles J, Alfaro TD, Wu J, Gao M, Slimane K, El Saghir NS.J Clin Oncol. 2024 May 21:JCO2400144. doi: 10.1200/JCO.24.00144. Online ahead of print.PMID: 38771995

BOLERO-5: A phase II study of Everolimus and Exemestane combination in Chinese post-menopausal women with ER+/HER2- advanced breast cancer, Z. Shao1, L. Cai2, S. Wang3, X. Hu4, K. Shen5, H. Wang6, H. Li7, J. Feng8, Q. Liu9, J. Cheng10, X. Wu11, X. Wang12, H. Li13, T. Luo14, J. Liu15, K. Amin16, K. Slimane17, Y. Qiao18, 2Y. Liu19, Z. Tong20

Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study. Diane Evrard, Clément Dumont, Michel Gatineau, Jean-Pierre Delord, Jérôme Fayette, Chantal Dreyer, Anne- milai Tijeras Raballand, Armand de Gramont, Jean François Delattre, Muriel Granier, Alexandra Hadengue, Nasredine Aissat6, MarieLine Garcia Larnicol, Khemaies Slimane, Benoist Chibaudel, Eric Raymond, Chris tophe Le Tourneau†, SandrineFaivre†Cancers 2022, 14(18),4509; https://doi.org/10.3390/cancers14184509

Efficacy and safety of ceritinib 450 mg/d with food and 750 mg/d in fasted state in treatment-naïve patients with ALK+ non-small cell lung cancer:. doi: 10.4143/crt.2021. Byoung Chul Cho, Dong-Wan Kim, Ullas Batra, Keunchil Park, Sang-We Kim, Cheng-Ta Yang, Pei-Jye Voon,7 Virote Sriuranpong, K. Govind Babu,Khalid Amin,10 Yingbo Wang, Paramita Saha, Khemaies Slimane, Sarayut Geater Cancer Res Treat. 2022 Mar 25

Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breastcancer: final results from EVEREXESYoung‑Hyuck Im Bulent Karabulut,· Keun Seok Lee,  Byeong‑Woo Park  Aditya Adhav · Havva Yesil Cinkir ·Hikmat Abdel‑Razeq, Yuan‑Ching Chang Sercan Aksoy · Seock‑Ah Im · Joon Jeong · Yeesoo Chae ·James Bowles · Khemaies Slimane Hongling Xue, Sung‑Bae Kim, Breast Cancer Research and Treatment Cancer Res Treat. 2022 Mar 25. doi: 10.4143/crt.2021.

Prospective Observational Study on Pazopanib in Patients Treated for Advanced or Metastatic Renal Cell Carcinoma in Countries in Asia Pacific, North Africa, and Middle East regions:  PARACHUTE Study   Mustafa. Ermana, Bivas. Biswasb, Pongwut. Danchaivijitrc, Lingwu. Chend, Yoke Fui Wonge, Tarek 6 Hashemf, Chun Sen Limg, Bulent Karabuluth, Hsiao-Jen Chungi, Chandra Chikatapuj, Sara Inglesk, 7 Khemaies Slimane, Ravindran Kanesvaranm.. BMC Cancer. 2021 Nov 9;21(1):1191.

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients. Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazieres J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenegre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B.ERJ Open Res. 2018 Feb 13;4(1). 

A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France. Joly F, Eymard JC, Albiges L, Nguyen T, Guillot A, Rolland F, Spaeth D, Laguerre B, Lebret T, Kelkouli N, Slimane K, Ravaud A. Support Care Cancer. 2017 Feb 10. doi: 10.1007/s00520-017-3594-y

Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study. Oudard S, Joly F, Geoffrois L, Laguerre B, Houede N, Barthelemy P, Gross-Goupil M, Vano Y, Lucidarme O, Bidault F, Kelkouli N, Slimane K, Escudier B. Clin Genitourin Cancer. 2016 May 2. pii: S1558-7673(16)30109-4. 

Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR trial.El-Madani M, Hénin E, Lefort T, Tod M, Freyer G, Cassier P, Valette PJ, Rodriguez-Lafrasse C, Berger F, Guitton J, Lachuer J, Slimane K, Barrois C, You B.Future Oncol. 2015;11(10):1511-8. doi: 10.2217/fon.15.49.

mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response.Lamuraglia M, Raslan S, Elaidi R, Oudard S, Escudier B, Slimane K, Penna RR, Wagner M, Lucidarme O. Eur Radiol. 2016 Jan;26(1):278-85. doi: 10.1007/s00330-015-3828-7. Epub 2015 May 8.

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma. Santos CD, Tijeras-Raballand A, Serova M, Sebbagh S, Slimane K, Faivre S, de Gramont A, Raymond E.Br J Cancer. 2014 Nov 25. doi: 10.1038/bjc.2014.578

Efficacy and safety of sequential use of everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab with or without interferon therapy: results from the European AVATOR study. Antoine Thiery-Vuillemin, Christine Theodore, Lutz Jacobasch, Jörg Schmitz, Christos Papandreou, Aline Guillot, Christos Emmanouilides, Khemaies Slimane, Nadia Kelkouli, Stefano Kim, Thierry Nguyen Tan Hon,. Clinical Genitourinary Cancer 2014 

 Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E.Cancer Chemother Pharmacol. 2013 May;71(5):1297-307. doi: 10.1007/s00280-013-2129-6. Epub 2013 Mar 12.

 Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction.Lebret T, Mouysset JL, Lortholary A, El Kouri C, Bastit L, Ktiouet M, Slimane K, Murraciole X, Guérif S.Support Care Cancer. 2013 Jun;21(6):1613-20. doi: 10.1007/s00520-012-1705-3. Epub 2013 Jan 9.

 Multicentric phase II clinical trial evaluating the role of everolimus (RAD001) in endemic or classic Kaposi's sarcoma (C06-46).Porcher R, Kerob D, Dupin N, Guillot B, Jouary T, Mathieu-Boue A, Slimane K, Furlan V, Battistella M, Agbalika F, Mourah S, Lebbé C. J Clin Oncol. 2011 May 20;29(15_suppl):10067.

Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy. De Crevoisier R, Slimane K, Messai T, Wibault P, Eschwege F, Bossi A, Koscielny S, Bridier A, Massard C, FizaziK.Ann Oncol. 2010 Apr;21(4):808-14.

Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX).de Crevoisier R, Slimane K, Sanfilippo N, Bossi A, Albano M, Dumas I, Wibault P, Fizazi K, Gerbaulet A, Haie-Meder C.Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1150-6. Epub 2009 Apr 22.

A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis.Khamaies S, Bethune-Volters A, Chidiac J, Bensaoula O, Delgado A, Di Palma M.Anticancer Drugs. 2006 Feb;17(2):217-24. Erratum in: Anticancer Drugs. 2006 Jun;17(5):599. Khamales, Slimane 

Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer.Andre F, Khalil A, Slimane K, Massard C, Mathieu MC, Vignot S, Assi H, Delaloge S, Spielmann M.J Clin Oncol. 2005 May 1;23(13):2996-3000.

Risk factors for brain relapse in patients with metastatic breast cancer. Slimane K, Andre F, Delaloge S, Dunant A, Perez A, Grenier J, Massard C, Spielmann M.Ann Oncol. 2004 Nov;15(11):1640-4.

Breast cancer with synchronous metastases: trends in survival during a 14-year period. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, Delaloge S, Spielmann M. J Clin Oncol. 2004 Aug 15;22(16):3302-8.

Management of emesis in cancer patients] Slimane K, Perez A, Ruffié P, di Palma M. Bull Cancer. 2004 May;91(5):403-8.

A prospective, comparative evaluation of the implementation of Good Clinical Practice (GCP) guidelines for preventing pain during invasive investigations in cancer patients (pts).Di Palma M, Salcedo H, Gaudebout P, Marie J, Franchi P, Belal F, Mauve J, Slimane K, Gasquet I, Misset JL.J Clin Oncol. 2004 Jul 15;22(14_suppl):8055.

Prognostic role of serum Ca 15-3 and circumstances of diagnostic in advanced breast cancer: Data from a prospective randomized trial. Rouzier R, Slimane K, Garbay JR, Arriagada R, Marsiglia H, Mathieu MC, Andre F, Delaloge S, Spielmann M. J Clin Oncol. 2004 Jul 15;22(14_suppl):810.

Epidermal growth factor receptor and chemoprevention of epithelial tumor: rationale and development methods] Masmoudi A, Fayette J, Slimane K, Temam S, Morat L, Soria JC. Bull Cancer. 2003 Nov;90 Spec No:S251-6. 

Overview of epidermal growth factor inhibitors (with the exclusion of ZD1839 and C225)] Slimane K, Fayette J, Masmoudi A, Perez A, Armand JP. Bull Cancer. 2003 Nov;90 Spec No:S213-9. 

The role of paclitaxel in the first line treatment of cancer of the ovary. Slimane K. Bull Cancer. 2003 Mar;90(3):202-3.